On the filings, Stryker (SYK) is the stronger stock right now — higher on our blended fundamentals-plus-verdict read, and we currently rate it HOLD.
Orthopedics steady-eddie: revenue grew 7% but earnings fell on one-time charges; full its multiple and weak 5.6% ROE cap upside.
Best-in-class MedTech compounder firing on all cylinders — but at ~40x GAAP earnings the price already pays for the quality.
| Metric | ZBH | SYK |
|---|---|---|
| Fundamentals score | 64 | 76 |
| Revenue growth (YoY) | +7.2% | +11.2% |
| Net income growth (YoY) | -22.0% | +8.5% |
| Net margin | 8.6% | 12.9% |
| Return on equity | 5.6% | 14.5% |
| ROIC (est.) | 4.3% | 10.1% |
| Liabilities / Equity | 0.82 | 1.13 |
| Piotroski F-score | 5 / 9 | 4 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 29, 2026, 5:43 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 29, 2026, 8:24 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.